Phenotypes associated with this allele

• Allele Symbol: Irf1^tm1Cwe
• Allele Name: targeted mutation 1, Charles Weissmann
• Allele ID: MGI:2429553
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Irf1^tm1Cwe/Irf1^tm1Cwe	involves: 129	MGI:3834969
hm2	Irf1^tm1Cwe/Irf1^tm1Cwe	involves: 129/Sv * C57BL/6	MGI:3834968

Genotype
MGI:3834969

hm1

• Allelic Composition: Irf1^tm1Cwe/Irf1^tm1Cwe
• Genetic Background: involves: 129

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal T cell proliferation ( J:84367 )

• higher background proliferation rates

• hyperproliferation requires higher MOGp35-55 peptide concentrations as a stimulus

abnormal cytokine level ( J:84367 )

• lower expression of lymphotoxin alpha and lymphotoxin beta after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

decreased circulating interferon-gamma level ( J:84367 )

• levels are reduced relative to controls after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

abnormal circulating interleukin-10 level ( J:84367 )

• detectable levels after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

increased circulating interleukin-13 level ( J:84367 )

• after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

abnormal circulating interleukin-4 level ( J:84367 )

• detectable levels after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

increased circulating interleukin-5 level ( J:84367 )

• after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

increased circulating interleukin-6 level ( J:84367 )

• after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:84367 )

• develop an attenuated disease after injection with MOGp35-55

• disease onset delayed about 4 days

hematopoietic system

abnormal T cell proliferation ( J:84367 )

• higher background proliferation rates

• hyperproliferation requires higher MOGp35-55 peptide concentrations as a stimulus

homeostasis/metabolism

abnormal cytokine level ( J:84367 )

• lower expression of lymphotoxin alpha and lymphotoxin beta after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

decreased circulating interferon-gamma level ( J:84367 )

• levels are reduced relative to controls after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

abnormal circulating interleukin-10 level ( J:84367 )

• detectable levels after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

increased circulating interleukin-13 level ( J:84367 )

• after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

abnormal circulating interleukin-4 level ( J:84367 )

• detectable levels after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

increased circulating interleukin-5 level ( J:84367 )

• after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

increased circulating interleukin-6 level ( J:84367 )

• after stimulation with anti-CD3 antibody or with MOGp35-55 peptide

cellular

abnormal T cell proliferation ( J:84367 )

• higher background proliferation rates

• hyperproliferation requires higher MOGp35-55 peptide concentrations as a stimulus

Genotype
MGI:3834968

hm2

• Allelic Composition: Irf1^tm1Cwe/Irf1^tm1Cwe
• Genetic Background: involves: 129/Sv * C57BL/6

immune system

abnormal immune system morphology ( J:21235 )

abnormal thymus cell ratio ( J:36025 )

• CD8+ population in the thymus is reduced 2.5 fold

abnormal T cell morphology ( J:21235 , J:36025 )

• 2-3 fold reduction in expression of MHC class I on thymocytes (J:21235)

• reduced expression of MHC class I on all T cell classes (J:36025)

increased T-helper 2 cell number ( J:110672 )

• shift from naive to Th2 effector cells by 2 months of age while total CD4+ cell numbers remain normal in the spleen

decreased CD8-positive, alpha-beta T cell number ( J:21235 )

• 85% reduction in CD8+ cells

abnormal splenocyte morphology ( J:21235 )

• 2-3 fold reduction in expression of MHC class I

abnormal immune system physiology ( J:43086 )

abnormal immunoglobulin level ( J:101427 )

• levels of IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virus

abnormal macrophage physiology ( J:43086 )

• fail to produce nitric oxide after stimulation with lipopolysaccharide or IFN-gamma either separately or in combination

abnormal cytokine level ( J:110672 )

increased circulating interferon-gamma level ( J:110672 )

• after stimulation with anti-CD28 antibody

decreased circulating interleukin-2 level ( J:110672 )

increased circulating interleukin-3 level ( J:110672 )

increased circulating interleukin-4 level ( J:110672 )

increased circulating interleukin-5 level ( J:110672 )

increased circulating interleukin-6 level ( J:110672 )

decreased susceptibility to induced arthritis ( J:43086 )

• reduced joint swelling, synovial hyperplasia and leukocyte infiltration after intra articular injections with Il-1beta

• response to lipopolysaccharide also milder

increased susceptibility to Poxviridae infection ( J:101427 )

• increased susceptibility to Ectromelia virus

• 100% mortality by day 6-12 after primary infection infection

• elevated virus titers in all organs tested after primary infection but much improved after secondary infections

• survive secondary infections

skeleton

skeleton phenotype ( J:43086 )

N • articular chondrocytes can be stimulated to nitric oxide production by Il-1

decreased susceptibility to induced arthritis ( J:43086 )

• reduced joint swelling, synovial hyperplasia and leukocyte infiltration after intra articular injections with Il-1beta

• response to lipopolysaccharide also milder

homeostasis/metabolism

abnormal cytokine level ( J:110672 )

increased circulating interferon-gamma level ( J:110672 )

• after stimulation with anti-CD28 antibody

decreased circulating interleukin-2 level ( J:110672 )

increased circulating interleukin-3 level ( J:110672 )

increased circulating interleukin-4 level ( J:110672 )

increased circulating interleukin-5 level ( J:110672 )

increased circulating interleukin-6 level ( J:110672 )

hematopoietic system

abnormal thymus cell ratio ( J:36025 )

• CD8+ population in the thymus is reduced 2.5 fold

abnormal T cell morphology ( J:21235 , J:36025 )

• 2-3 fold reduction in expression of MHC class I on thymocytes (J:21235)

• reduced expression of MHC class I on all T cell classes (J:36025)

increased T-helper 2 cell number ( J:110672 )

• shift from naive to Th2 effector cells by 2 months of age while total CD4+ cell numbers remain normal in the spleen

decreased CD8-positive, alpha-beta T cell number ( J:21235 )

• 85% reduction in CD8+ cells

abnormal splenocyte morphology ( J:21235 )

• 2-3 fold reduction in expression of MHC class I

abnormal immunoglobulin level ( J:101427 )

• levels of IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virus

abnormal macrophage physiology ( J:43086 )

• fail to produce nitric oxide after stimulation with lipopolysaccharide or IFN-gamma either separately or in combination

endocrine/exocrine glands

abnormal thymus cell ratio ( J:36025 )

• CD8+ population in the thymus is reduced 2.5 fold